Lansforsakringar Fondforvaltning AB publ Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Lansforsakringar Fondforvaltning AB publ purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 42,544 shares of the biopharmaceutical company's stock, valued at approximately $10,011,000.

Several other institutional investors and hedge funds have also modified their holdings of ALNY. Jennison Associates LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $61,160,000. Strategic Financial Concepts LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $41,529,000. Truist Financial Corp raised its holdings in Alnylam Pharmaceuticals by 136.6% in the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after buying an additional 2,539 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after buying an additional 8,462 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Alnylam Pharmaceuticals by 7.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 38,997 shares of the biopharmaceutical company's stock valued at $9,176,000 after buying an additional 2,657 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 0.5%

NASDAQ ALNY traded up $1.53 during mid-day trading on Monday, hitting $306.09. The company's stock had a trading volume of 1,131,431 shares, compared to its average volume of 929,247. The company's 50 day simple moving average is $261.12 and its 200 day simple moving average is $255.48. Alnylam Pharmaceuticals, Inc. has a twelve month low of $147.25 and a twelve month high of $307.19. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $39.91 billion, a price-to-earnings ratio of -141.05 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same period in the prior year, the firm posted ($0.16) earnings per share. The company's revenue for the quarter was up 20.2% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Royal Bank of Canada raised their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a report on Friday, March 21st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $280.00 to $328.00 in a report on Monday, March 24th. Stifel Nicolaus raised their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday, March 31st. Finally, Redburn Atlantic assumed coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $319.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.